Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture

Journal of Pineal Research

Volumn 43, Issue 2, 2007, Pages 195-205

  García Navarro, Ana ^a   González Puga, Cristina ^a   Escames, Germaine ^b   López, Luis C ^b   López, Ana ^b   López Cantarero, Manuel ^b   Camacho, Encarnación ^c   Espinosa, Antonio ^c   Gallo, Miguel Angel ^c   Acuña Castroviejo, Darío ^a,d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antioxidant; HT 29 cancer cells; Melatonin; Melatonin receptors; Nitric oxide; Oncostatic therapy; Oxidative stress

Indexed keywords

1 (3 ALLYL 4 OXO 2 THIAZOLIDINYLIDENE) 4 METHYLTHIOSEMICARBAZONE; 2 ACETAMIDE 4 (2 AMINO 5 METHOXYPHENYL) 4 OXOBUTYRIC ACID; 2 ACETAMIDE 4 (3 METHOXYPHENYL) 4 OXOBUTYRIC ACID; 2 BUTYRAMIDE 4 (2 AMINO 5 METHOXYPHENYL) 4 OXOBUTYRIC ACID; 2 BUTYRAMIDE 4 (3 METHOXYPHENYL) 4 OXOBUTYRIC ACID; 2 IODO N BUTANOYL 5 METHOXYTRYPTAMINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; AMINO ACID DERIVATIVE; CELL NUCLEUS RECEPTOR; CYCLIC NUCLEOTIDE; DNA; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GR 135531; INDOLE DERIVATIVE; KYNURENINE; LUZINDOLE; MELATONIN; MELATONIN RECEPTOR; MEMBRANE RECEPTOR; NITRIC OXIDE; NITRITE; PRAZOSIN; THYMIDINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL;

CELL PROLIFERATION; COLONIC NEOPLASMS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KYNURENINE; MELATONIN; MOLECULAR STRUCTURE; RECEPTORS, MELATONIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIOSEMICARBAZONES;

EID: 34447500401     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2007.00463.x     Document Type: Article

References (78)

1. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cell (MCF-7) in culture. Cancer Res 1988 48 : 6121 6126.
2. Papazisis KT, Kouretas D, Geromichalos GD et al. Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 1998 25 : 211 218.
3. Baldwin PJ, Bierman W, Jayadev J et al. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999 26 : 129 136.
4. Farriol M, Venereo Y, Orta X et al. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000 20 : 21 24.
5. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002 2 : 113 132.
6. Anisimov VN, Popovich IG, Zabezhinski MA et al. Melatonin: antioxidant, genoprotector and anticarcinogen. Biochim Biophys Acta 2006 1757 : 573 589.
7. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005 27 : 179 188.
8. Lissoni P, Barni S, Tancini G et al. Study of the mechanism involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993 50 : 399 402.
9. Carrillo-Vico A, Guerrero JM, Lardone PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005 27 : 189 200.
10. Miller SC, Panid-Perumal SR, Esquifino A et al. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006 87 : 81 87.
11. González-Puga C, García-Navarro A, Escames G et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res 2005 39 : 243 250.
12. Barret P, Conway S, Morgan PJ. Digging deep - structure-function relationships in the melatonin receptor family. J Pineal Res 2003 35 : 221 230.
13. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995 16 : 50 56.
14. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 1996 17 : 100 102.
15. Shiu SYW, NG N, Pang SF. A molecular perspective of the genetic relationships of Gprotein coupled melatonin receptor subtypes. J Pineal Res 1996 20 : 198 204.
16. Shiu SYW, LI L, XU JN et al. Melatonin-induced inhibition of proliferation and G1/S cell cycle, transition delay of human choriocarcinoma Jar cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 1999 27 : 183 192.
17. Costa Ejx, Harzer Lopes R, Lamy-Freund MT. Permeability of pure lipid bilayers to melatonin. J Pineal Res 1995 19 : 123 126.
18. Menendez-Pelaez A, Poeggeler B, Reiter RJ et al. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J Cell Biochem 2003 53 : 373 382.
19. Acuña-Castroviejo D, Reiter RJ, Menéndez-Pelaez A et al. Characterization of high affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 1994 16 : 12.
20. Wiesenberg I, Missbach M, Kahlen JP et al. Identification of nuclear receptor mRNAs by TR-PCR transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995 23 : 327 333.
21. Karasek M, Pawlikowski M. Antiproliferative effects of melatonin and CGP 52608. Biol Signals Recept 1999 8 : 75 78.
22. Andrabi SA, Sayeed I, Siemen D et al. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004 18 : 869 871.
23. Jou MJ, Peng TI, Reirer RJ, Jou SB, WU HY, Wen ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004 37 : 55 70.
24. Shida CS, Castrucci AM, Lamy-Freund MT. High melatonin solubility in aqueous medium. J Pineal Res 1994 16 : 198 201.
25. Benítez-King G, Antón-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia 1993 49 : 635 641.
26. Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Melatonin modifies calmodulin cell levels in MDCK and N1E-1 15 cells lines and inhibits phosphodiestearase activity in vitro. Brain Res 1991 557 : 289 292.
27. León J, Macías M, Escames G et al. Structure-related inhibition of calmodulin-dependent nNOS activity by melatonin and synthetic kynurenines. Mol Pharmacol 2000 58 : 967 975.
28. León J, Escames G, Rodríguez MI et al. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 2006 98 : 2023 2033.
29. Benítez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006 40 : 1 9.
30. Thomsen LL, Lawtron FG, Knowles RG et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994 54 : 1352 1354.
31. Lagares-Garcia JA, Moore RA, Collier B et al. Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 2001 67 : 709 713.
32. Yagihashi N, Kasajima H, Sugai S et al. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 2000 436 : 109 114.
33. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001 33 : 735 753.
34. Reiter RJ, Tan DX, Manchester LC et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochem Biophys 2001 34 : 237 256.
35. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
36. Vijayalaxmi, Reiter RJ, Meltz ML. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res 1995 346 : 23 31.
37. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 1997 57 : 1909 1914.
38. Panzer A, Viljoen M. The validity of melatonin as an oncostatic agent. J Pineal Res 1997 22 : 184 202.
39. Camacho E, León J, Carrión A et al. Inhibition of nNOS activity in rat brain by synthetic kynurenines: structure-activity dependence. J Med Chem 2002 45 : 263 274.
40. Skehan P. Assays of cell growth and cytotoxicity. In : Cell Growth and Apoptosis: A Practical Approach. Stuzinski CC, ed. Oxford Press, New York, 1991 pp. 169 191.
41. Green LC, Ruiz DE, Luzuriaga K, Wagner DA. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981 78 : 7764 7768.
42. Lowry OH, Rosenbrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 275.
43. Hissin PJ, Hilf R. A fluorimetric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976 74 : 214 226.
44. Jaskot RH, Charlet EG, Grose EC et al. An automatic analysis of glutathione peroxidase, glutathione-S-transferase, and reductase activity in animal tissue. J Anal Toxicol 1983 7 : 86 88.
45. Tallarida, RJ, Murray RB, eds. Manual of Pharmacological Calculations with Computer Programs. Springer-Verlag, New York, 1986.
46. Lewinski A, Rybicka I, Wajs E et al. Influence of pineal indoleamines on the mitotic activity of gastric and colonic mucosa epithelial cells in the rat: interaction with omeprazole. J Pineal Res 1991 10 : 104 108.
47. Callaghan BD. The effects of pinealectomy on the crypts of defunctioned rat colon. J Pineal Res 1997 23 : 117 122.
48. Anisimov VN, Popovich IG, Zabezhinski M. Melatonin and colon carcinogenesis. I. Inhibitory effects of melatonin on development of intestinal tumors induced by 1,2-dimethyl-hidrazyne in rats. Carcinogenesis 1997 18 : 1549 1553.
49. Chen ID, Leal BZ, Reiter RJ et al. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione levels. Cancer Lett 1995 91 : 153 159.
50. Maestroni GJ, Conti A. Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab Invest 1996 75 : 557 561.
51. Lissoni P, Paolorossi F, Tancini G et al. A phase II study of tamoxifem plus melatonin in metastatic solid tumour patients. Br J Cancer 1996 74 : 1466 1468.
52. Mills E, WU P, Seely D et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005 39 : 360 366.
53. Persengiev SF, Kyurkchiev S. Selective effect of melatonin on the proliferation of lymphoid cells. Int J Biochem 1993 25 : 441 444.
54. Witt-Enderby PA, Radio NM, Doctor JS et al. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and adjuvant therapy. J Pineal Res 2006 41 : 297 305.
55. Poon AM, Mak AS, Luk HT. Melatonin and 2[1251]iodomelatonin binding sites in the human colon. Endocr Res 1996 22 : 77 94.
56. Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994 269 : 28531 28534.
57. Carlberg C, Wiesenberg I, Schräder M. Nuclear signaling of melatonin. Front Horm Res 1997 23 : 25 35.
58. Hirose T, Smith RJ, Jetten AM. ROR The third member of ROR/RZR orphan receptor subfamily that highly expressed in skeletal muscle. Biochem Biophys Res Commun 1994 205 : 1976 1983.
59. Steinhilber D, Brungs M, Werz O et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995 270 : 7037 7040.
60. Dai J, Ram PT, Yuan L et al. Transcriptional repression os RORalpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol 2001 176 : 111 120.
61. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 1998 12 : 143 150.
62. Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21 WAF 1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999 65 : 415 420.
63. Camacho E, León J, Carrión MD et al. Inhibition of nNOS activity in rat brain by synthetic kynurenines: structure-activity dependence. J Med Chem 2002 45 : 263 274.
64. Escames J, León L, López LC et al. Mechanisms of the NMDA receptor inhibition by melatonin in the rat brain striatum. J Neuroendocrinol 2004 16 : 929 935.
65. Crespo E, Maclas M, Pozo D et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999 13 : 1537 1546.
66. Escames G, León J, Macías M et al. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003 17 : 932 934.
67. Vanderwinden JM. Role of nitric oxide in gastrointestinal function and disease. Acta Gastroenterol Belg 1994 57 : 224 229.
68. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumor progression. Lancet 2001 2 : 149 156.
69. Forrester K, Ambs S, Lupold SE et al. Nitric oxide induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild type p53. Proc Natl Acad Sci USA 1996 93 : 2442 2447.
70. Ho YS, Wang YJ, Lin JK. Induction of p53 and p21/WAFI/CIF1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinol 1996 16 : 20 31.
71. Ambs S, Bennet WP, Merrium WG et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999 91 : 86 88.
72. Kojima M, Morisaki T, Tsukahara Y et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 1999 70 : 222 229.
73. Salim AS. The permissive role of oxygen-free radicals in the development of colonic cancer in the rat. Int J Cancer 1993 53 : 1031 1035.
74. Gius D, Spitz DR. Redox signaling in cancer biology. Antioxid Redox Signal 2006 8 : 1249 1252.
75. Kim GJ, Chandrasekaran K, Morgan WF. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 2006 21 : 361 367.
76. Wenzel U, Nickel A, Daniel H. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. Int J Cancer 2005 116 : 236 242.
77. Rodríguez C, Mayo JC, Sainz RM. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004 36 : 1 9.
78. Tomás-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005 39 : 99 104.